Clinical Trial

Phase I Study of FXS887 in the Treatment of Solid Tumors

Name: Phase I Study of FXS887 in the Treatment of Solid Tumors — clinical trial record (NCT07345637)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: FXS887-I101

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This is a single-arm, open-label, dose-escalation and dose-expansion Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of FXS887 in patients with advanced solid tumors. FXS887 is a innovative ATR inhibitors of a class of small-molecule inhibitors targeting ATR kinase.

Trial Details

NCT Number	NCT07345637
Lead Sponsor	Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Conditions	Solid Tumor Refractory to Conventional Treatment
Enrollment	14 participants
Start Date	2026-01-05
Primary Completion	2027-04-28 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-01-16